EQ Fundamental Analysis - EQUILLIUM INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to EQ. EQ was compared to 557 industry peers in the Biotechnology industry. While EQ seems to be doing ok healthwise, there are quite some concerns on its profitability. EQ is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

EQ had negative earnings in the past year.

In the past year EQ has reported a negative cash flow from operations.

In the past 5 years EQ always reported negative net income.

In the past 5 years EQ always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of EQ (-83.61%) is worse than 71.81% of its industry peers.

With a Return On Equity value of -132.23%, EQ is not doing good in the industry: 60.14% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-83.61%
ROE	-132.23%
ROIC	N/A

ROA(3y)-45.84%

ROA(5y)-43.62%

ROE(3y)-98.95%

ROE(5y)-79.65%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EQ does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, EQ has more shares outstanding

Compared to 5 years ago, EQ has more shares outstanding

There is no outstanding debt for EQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -16.04, we must say that EQ is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of EQ (-16.04) is worse than 81.51% of its industry peers.

There is no outstanding debt for EQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-16.04

ROIC/WACCN/A

WACC9.05%

2.3 Liquidity

EQ has a Current Ratio of 2.70. This indicates that EQ is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of EQ (2.70) is worse than 68.04% of its industry peers.

EQ has a Quick Ratio of 2.70. This indicates that EQ is financially healthy and has no problem in meeting its short term obligations.

EQ has a Quick ratio of 2.70. This is in the lower half of the industry: EQ underperforms 66.43% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.7
Quick Ratio	2.7

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EQ have decreased by -8.33% in the last year.

EQ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.75%.

EPS 1Y (TTM)-8.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-200%

Revenue 1Y (TTM)-19.75%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

EQ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.60% yearly.

Based on estimates for the next years, EQ will show a quite strong growth in Revenue. The Revenue will grow by 19.44% on average per year.

EPS Next Y-280.65%

EPS Next 2Y-120.94%

EPS Next 3Y-51.08%

EPS Next 5Y11.6%

Revenue Next Year-100%

Revenue Next 2Y-52.55%

Revenue Next 3Y12.09%

Revenue Next 5Y19.44%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EQ. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

EQ's earnings are expected to decrease with -51.08% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-120.94%

EPS Next 3Y-51.08%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EQ does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EQUILLIUM INC

NASDAQ:EQ (6/16/2025, 8:00:01 PM)

Premarket: 0.3301 -0.01 (-2.94%)

0.3401

-0.01 (-1.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-14 2025-05-14/amc

Earnings (Next)08-06 2025-08-06

Inst Owners19.59%

Inst Owner Change-0.52%

Ins Owners24.24%

Ins Owner Change0%

Market Cap12.15M

Analysts42

Price Target1.02 (199.91%)

Short Float %0.39%

Short Ratio0.12

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)40.17%

Min EPS beat(2)30.44%

Max EPS beat(2)49.89%

EPS beat(4)4

Avg EPS beat(4)71.7%

Min EPS beat(4)30.44%

Max EPS beat(4)106.47%

EPS beat(8)8

Avg EPS beat(8)59.13%

EPS beat(12)11

Avg EPS beat(12)77.81%

EPS beat(16)12

Avg EPS beat(16)57.23%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-75%

EPS NQ rev (1m)-32.14%

EPS NQ rev (3m)-2.78%

EPS NY rev (1m)0%

EPS NY rev (3m)1.16%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.4
P/FCF	N/A
P/OCF	N/A
P/B	1.15
P/tB	1.15
EV/EBITDA	N/A

EPS(TTM)-0.39

EYN/A

EPS(NY)-1.12

Fwd EYN/A

FCF(TTM)-0.52

FCFYN/A

OCF(TTM)-0.51

OCFYN/A

SpS0.85

BVpS0.3

TBVpS0.3

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-83.61%
ROE	-132.23%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-45.84%

ROA(5y)-43.62%

ROE(3y)-98.95%

ROE(5y)-79.65%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover1.82

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	50.72%
Cap/Sales	0.23%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.7
Quick Ratio	2.7
Altman-Z	-16.04

F-Score3

WACC9.05%

ROIC/WACCN/A

Cap/Depr(3y)111.69%

Cap/Depr(5y)164.16%

Cap/Sales(3y)0.71%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-8.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-200%

EPS Next Y-280.65%

EPS Next 2Y-120.94%

EPS Next 3Y-51.08%

EPS Next 5Y11.6%

Revenue 1Y (TTM)-19.75%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

Revenue Next Year-100%

Revenue Next 2Y-52.55%

Revenue Next 3Y12.09%

Revenue Next 5Y19.44%

EBIT growth 1Y-8.68%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-296.24%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-299.89%

OCF growth 3YN/A

OCF growth 5YN/A

EQUILLIUM INC (EQ) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens